PERSON DIRECTORY
Lukas Biewald
Host of Gradient Dissent. Lukas Biewald appears in 23 indexed conversations across Gradient Dissent. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.
Curing Every Disease With Al by 2050 | Sam Rodriques, Edison Scientific
Robin generated a dry age-related macular degeneration treatment hypothesis that reached animal validation before publication in Nature in May 2025.Cosmos has since produced an estimated 20,000-30,000 proposed findings, expanding throughput while human trials remain the physical bottleneck.Phase 3 success or FDA approval is the credibility catalyst, while Edison’s specialized, multi-model moat could weaken if general models reach task saturation.
From pharma to AGI hype, and developing AI in finance: Martin Shkreli’s journey
AI’s largest biopharma opportunity may be target selection rather than molecule generation, with an LLM reading roughly 36-38 million PubMed papers to identify overlooked clinical opportunities.BTK illustrates the mechanism: valuable research sat published for 15-20 years, while clinical trials still consume 50-70% of total cost and development cycles approach ten years.Shkreli’s finance suite found millions of dollars in revenue after abandoning forced AI positioning, but breaking-news advantages may diffuse across Wall Street within six months to a year.